CN110022869A - 用于皮肤和/或毛发修复的5-羟色胺1b受体刺激剂 - Google Patents

用于皮肤和/或毛发修复的5-羟色胺1b受体刺激剂 Download PDF

Info

Publication number
CN110022869A
CN110022869A CN201780055993.4A CN201780055993A CN110022869A CN 110022869 A CN110022869 A CN 110022869A CN 201780055993 A CN201780055993 A CN 201780055993A CN 110022869 A CN110022869 A CN 110022869A
Authority
CN
China
Prior art keywords
skin
hair
vortioxetine
damage
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780055993.4A
Other languages
English (en)
Chinese (zh)
Inventor
R·盖拉德
F·B·克雷蒂安
P·罗切托
N·托诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Paris Descartes
Centre Hospitalier Sainte-Anne
Institut Pasteur
Original Assignee
Université Paris Descartes
Centre Hospitalier Sainte-Anne
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Paris Descartes, Centre Hospitalier Sainte-Anne, Institut Pasteur filed Critical Université Paris Descartes
Publication of CN110022869A publication Critical patent/CN110022869A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/002—Preparations for repairing the hair, e.g. hair cure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A61K2800/884—Sequential application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780055993.4A 2016-07-15 2017-07-13 用于皮肤和/或毛发修复的5-羟色胺1b受体刺激剂 Pending CN110022869A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2016/001136 2016-07-15
IB2016001136 2016-07-15
PCT/EP2017/067791 WO2018011382A1 (en) 2016-07-15 2017-07-13 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair

Publications (1)

Publication Number Publication Date
CN110022869A true CN110022869A (zh) 2019-07-16

Family

ID=56787641

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780055993.4A Pending CN110022869A (zh) 2016-07-15 2017-07-13 用于皮肤和/或毛发修复的5-羟色胺1b受体刺激剂

Country Status (10)

Country Link
US (1) US20190290641A1 (cg-RX-API-DMAC7.html)
EP (1) EP3484462B1 (cg-RX-API-DMAC7.html)
JP (1) JP2019524723A (cg-RX-API-DMAC7.html)
KR (1) KR20190038840A (cg-RX-API-DMAC7.html)
CN (1) CN110022869A (cg-RX-API-DMAC7.html)
AU (1) AU2017295038B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019000706A8 (cg-RX-API-DMAC7.html)
CA (1) CA3030054A1 (cg-RX-API-DMAC7.html)
MX (1) MX386989B (cg-RX-API-DMAC7.html)
WO (1) WO2018011382A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3799873A1 (en) 2015-07-17 2021-04-07 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
BR112020026099A2 (pt) * 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
CA3158781A1 (en) * 2019-10-23 2021-04-29 Michael Wood Methods of treating the symptoms of autism spectrum disorder
CN115919860B (zh) * 2022-12-05 2023-11-10 中国药科大学 氟班色林在制备治疗雄激素脱发药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101668526A (zh) * 2006-12-22 2010-03-10 梅迪斯蒂国际股份有限公司 抗抑郁化合物和相关组合物的新用途
CN104736176A (zh) * 2012-08-24 2015-06-24 英特格拉斯疗法有限公司 用于增强治疗剂透皮递送的化学组合物和方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63203625A (ja) 1987-02-19 1988-08-23 Kao Corp 5α−リダクタ−ゼ阻害剤
FR2739553B1 (fr) 1995-10-06 1998-01-02 Oreal Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
FR2758263B1 (fr) * 1997-01-16 1999-12-17 Oreal Utilisation d'un antagoniste ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
FR2778558B1 (fr) 1998-05-12 2001-02-16 Oreal Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
ES2147538B1 (es) 1999-01-29 2001-04-01 Revlon Consumer Prod Corp Una locion capilar con propiedades mejoradas en su accion protectora del cabello y preventiva de su caida, y de reduccion de los efectos externos de la alopecia androgenetica y con ello de la caida del cabello.
JP3441665B2 (ja) 1999-02-04 2003-09-02 株式会社資生堂 (2−置換オキシフェニル)アルカンアミド誘導体及び養毛剤、皮膚外用剤
US20060052405A1 (en) 2000-07-19 2006-03-09 Knowles W R Hair loss prevention
FR2812192B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
ATE316387T1 (de) * 2000-09-22 2006-02-15 Perlei Medical Produkte Gmbh Verwendung von antifibrinolytika für die präparation und herstellung von tupfern, kompressen oder pflaster
ES2267945T3 (es) 2001-05-31 2007-03-16 Pfizer Products Inc. Uso medico de compuestos tiromimeticos para tratar la perdida del cabello y composiciones.
EP1435899B1 (en) 2001-09-28 2009-03-11 LG Household &amp; Health Care Ltd. A composition for promoting hair growth
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US6860042B2 (en) 2002-07-19 2005-03-01 Walker-Dawson Interests, Inc. Excavation system employing a jet pump
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
ATE407724T1 (de) 2002-11-12 2008-09-15 Warner Lambert Co Methode zur stimulierung von haarwuchs auf der basis von benzopyranen
CA2511089A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc Androgen receptor antagonists
ES2436524T3 (es) 2003-05-22 2014-01-02 Nerviano Medical Sciences S.R.L. Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
US20050118282A1 (en) 2003-09-16 2005-06-02 Aphios Corporation Compositions and methods for inhibiting 5-alpha reductase
AR041407A1 (es) 2003-09-26 2005-05-18 Nestor Alberto Kerner Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento
US20060009430A1 (en) 2004-07-01 2006-01-12 Kelly Gregory J Composition for the prevention and treatment of the detrimental effects of dihydrotestosterone
MXPA06015169A (es) 2004-07-08 2007-08-21 Warner Lambert Co Moduladores de androgenos.
DE202006007482U1 (de) 2006-05-10 2006-07-20 Sentner, Thomas Leuchtmöbel
MY150647A (en) * 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
CN101506188B (zh) * 2006-06-22 2014-01-15 雷蒙特亚特特拉维夫大学有限公司 作为具外周系统限制活性药物的五羟色胺再摄取抑制剂
FR2903984B1 (fr) 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
WO2008084286A2 (en) * 2006-10-25 2008-07-17 Arterial Remodeling Technologies, S.A. Method for expansion and deployment of polymeric structures including stents
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US20100092454A1 (en) * 2006-12-22 2010-04-15 Enrico De Vivo novel use of antidepressant compounds and related compositions
EP2490669B1 (en) * 2009-10-23 2017-01-11 Fortuderm Ltd. Triptans for the treatment of psoriasis
ES2622138T3 (es) 2010-06-23 2017-07-05 Hanmi Science Co., Ltd. Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa
US20160101093A1 (en) * 2013-05-21 2016-04-14 Jason B. Wynberg Methods for the treatment of premature ejaculation
US9399039B1 (en) * 2015-06-30 2016-07-26 University Of South Florida Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101668526A (zh) * 2006-12-22 2010-03-10 梅迪斯蒂国际股份有限公司 抗抑郁化合物和相关组合物的新用途
CN104736176A (zh) * 2012-08-24 2015-06-24 英特格拉斯疗法有限公司 用于增强治疗剂透皮递送的化学组合物和方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
任莹莹等: "靶向单胺受体及谷氨酸系统抗抑郁药的研究进展", 《药物资讯》 *
李燕: "He-Ne激光、LED及氯胺酮对成纤维细胞影响的初步研究", 《中国优秀博硕士学位论文全文数据库(硕士) 基础科学辑》 *

Also Published As

Publication number Publication date
AU2017295038B2 (en) 2022-09-22
BR112019000706A8 (pt) 2022-12-06
EP3484462B1 (en) 2022-12-14
KR20190038840A (ko) 2019-04-09
JP2019524723A (ja) 2019-09-05
EP3484462A1 (en) 2019-05-22
AU2017295038A1 (en) 2019-01-24
CA3030054A1 (en) 2018-01-18
US20190290641A1 (en) 2019-09-26
MX386989B (es) 2025-03-19
BR112019000706A2 (pt) 2019-05-07
WO2018011382A1 (en) 2018-01-18
MX2019000600A (es) 2019-06-13

Similar Documents

Publication Publication Date Title
EP3484462B1 (en) 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
US20210330863A1 (en) 5-hydroxytryptamine 1b receptor-stimulating agent for enhancing in vivo engraftment potential
EP3573957A1 (en) Compositions and methods for blocking sodium channels
CN101903009A (zh) 含有脱硫生物素及其衍生物的局部组合物和治疗皮肤的方法
JP2008509900A6 (ja) 選択的ノルアドレナリン再取込阻害剤およびpdev阻害剤の配合物
JP2008509900A (ja) 選択的ノルアドレナリン再取込阻害剤およびpdev阻害剤の配合物
KR101427163B1 (ko) Pde5 억제제를 함유하는 피부 주름 개선용 조성물
JP2025071027A (ja) チモールエステル系化合物を含む皮膚老化の予防または改善用組成物
KR102723050B1 (ko) Bcl-2 억제제를 포함하는 항노화 및 피부 미백용 조성물
EP3829623A1 (en) Methods for reducing abnormal scar formation
JP2017537880A (ja) Abh抗原の発現を調節する物質を含む組成物
CA3248815A1 (en) Topical compositions and their uses
CN115721575A (zh) 缓和皮肤敏感性或者抑制皮脂分泌用组合物
HK1256597A1 (zh) 含有细胞老化抑制剂作为有效成分的皮肤皱纹改善用及皮肤损伤炎症疾病治疗用组合物
WO2016099397A1 (en) 3-(piperidin-4-yl)-isoxazol-3(2h)-ones for treatment of dermatologic disorders
JP2004331664A (ja) ピリミジン−n−オキシド誘導体を含有する毛髪用組成物、ケラチン繊維の成長を刺激し及び/又は抜毛を減少させるためのその使用
JP2008230974A (ja) 育毛料
WO2023056029A1 (en) Beta3-adrenergic agonists for treatment of disorders of hair growth
WO2026013449A2 (en) Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
JP2008528539A (ja) 毛および睫毛の成長促進のための、ならびに/またはこれらの損失および/もしくは脱色素の制限のための3−スルファニルプロパンアミド類の使用
JP2025041554A (ja) チモールエステル系化合物を含む皮膚活力増強用組成物
KR20170134109A (ko) 타베르소닌을 포함하는 탈모방지 및 발모 촉진용 조성물
KR20230154641A (ko) 설포라판을 유효성분으로 포함하는 피부 질환의 예방, 개선 또는 치료용 조성물
KR101577053B1 (ko) 트리아졸 유도체를 포함하는 탈모 예방 및 발모 촉진용 조성물과 탈모 예방 및 발모 촉진용 화장료 조성물
ES2383858B1 (es) Compuestos marinos antagonistas de los canales de calcio para el tratamiento de enfermedades cardiovasculares.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190716